haloperidol and Dizzyness studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

Excerpt	Relevance	Reference
"Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial."	9.09	Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001)
"Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial."	5.09	Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001)
"Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized."	4.79	Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline in Body Mass Index (BMI)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Park, CH	1
Park, TW	1
Yang, JC	1
Lee, KH	1
Huang, GB	1
Tong, Z	1
Park, MS	1
Chung, YC	1
Beasley, CM	1
Tollefson, GD	1
Tran, PV	1
Kane, JM	1
Marder, SR	1
Schooler, NR	1
Wirshing, WC	1
Umbricht, D	1
Baker, RW	1
Wirshing, DA	1
Safferman, A	1
Ganguli, R	1
McMeniman, M	1
Borenstein, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]	Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Fasting Total Cholesterol

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.4
Placebo	0.3

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Intervention	mg/dL (Mean)
Aripiprazole	-3
Placebo	9

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Low-density Lipoprotein (LDL)

Intervention	mg/dL (Mean)
Aripiprazole	0.4
Placebo	0.6

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Triglycerides

Intervention	mg/dL (Mean)
Aripiprazole	-0.2
Placebo	3.1

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Waist-hip Ratio (WHR)

Intervention	mg/dL (Mean)
Aripiprazole	-51.7
Placebo	47.6

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Weight (Lbs)

Intervention	cm (Mean)
Aripiprazole	0.0
Placebo	0.0

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Article	Year
No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. International clinical psychopharmacology, 2012, Volume: 27, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dizziness; Double-Bli	2012
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of general psychiatry, 2001, Volume: 58, Issue:10 Topics: Adult; Anorexia; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Dizziness; Dose-Re	2001

haloperidol and Dizzyness